REGENXBIO Inc. (NASDAQ:RGNX) Director Sells $115,600.00 in Stock

REGENXBIO Inc. (NASDAQ:RGNX) Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $11.56, for a total transaction of $115,600.00. Following the sale, the director now directly owns 11,286 shares in the company, valued at approximately $130,466.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

REGENXBIO Stock Performance

RGNX stock opened at $11.38 on Friday. The company has a 50 day moving average price of $12.29 and a two-hundred day moving average price of $15.59. The stock has a market capitalization of $562.40 million, a P/E ratio of -1.94 and a beta of 1.22. REGENXBIO Inc. has a one year low of $10.49 and a one year high of $28.80.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.24. REGENXBIO had a negative return on equity of 68.21% and a negative net margin of 270.74%. The company had revenue of $22.30 million during the quarter, compared to analysts’ expectations of $22.97 million. During the same quarter in the previous year, the business earned ($1.66) EPS. The firm’s revenue was up 11.6% on a year-over-year basis. Research analysts forecast that REGENXBIO Inc. will post -4.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On REGENXBIO

Institutional investors and hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. grew its position in REGENXBIO by 73.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 746 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in REGENXBIO during the 1st quarter worth approximately $56,000. Headlands Technologies LLC raised its holdings in REGENXBIO by 276.8% in the first quarter. Headlands Technologies LLC now owns 3,828 shares of the biotechnology company’s stock valued at $81,000 after buying an additional 2,812 shares during the period. Diversified Trust Co acquired a new position in REGENXBIO during the second quarter valued at approximately $121,000. Finally, Arizona State Retirement System lifted its position in REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 1,997 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

Analyst Upgrades and Downgrades

RGNX has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $39.00 price target on shares of REGENXBIO in a research note on Wednesday. Barclays lowered their target price on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Tuesday, June 18th. Finally, The Goldman Sachs Group initiated coverage on shares of REGENXBIO in a research report on Friday, June 7th. They issued a “buy” rating and a $38.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, REGENXBIO has an average rating of “Moderate Buy” and a consensus target price of $37.91.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.